Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Radical-omics reveals the hydrogen-abstraction pathway of isoprene oxidation.

Nature communications·2026
Same author

Risk of perinatal psychiatric disorder among women with a history of premenstrual disorder: a nationwide register-based study from Sweden.

BMJ open·2026
Same author

From Foundation to Intelligence Integration: The Synergistic Associations of ICT and AI Support with Pre-Service Teachers' TPACK Development.

Behavioral sciences (Basel, Switzerland)·2026
Same author

Genomic structural equation modelling of 12 cancers identifies a latent pan-cancer susceptibility factor and shared determinants of carcinogenesis.

EBioMedicine·2026
Same author

Corrigendum to "Shengxian decoction mitigate bleomycin-induced pulmonary fibrosis in mice via MerTK mediated macrophage efferocytosis" [J. Ethnopharmacol. 365 (2026) 121583].

Journal of ethnopharmacology·2026
Same author

Cohort profile: transformative research on equity and social determinants to uplift resilience and empower LGBTQ+ health in China (TREASURE).

European journal of epidemiology·2026
Same journal

Interventions to prevent or cease electronic cigarette use in children and adolescents.

The Cochrane database of systematic reviews·2026
Same journal

Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS).

The Cochrane database of systematic reviews·2026
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
See all related articles

Related Experiment Video

Updated: May 26, 2026

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

Naftidrofuryl for dementia.

Donghao Lu1, Huan Song, Zilong Hao

  • 1Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, No. 20, Third Section of Ren Min Nan Road, Chengdu, Sichuan, China, 610041.

The Cochrane Database of Systematic Reviews
|December 14, 2011
PubMed
Summary
This summary is machine-generated.

Naftidrofuryl, a vasodilatory drug, may offer benefits for dementia patients in areas like performance, behavior, cognition, and mood. While generally well-tolerated, its overall effectiveness on global impression remains inconclusive based on current evidence.

Related Experiment Videos

Last Updated: May 26, 2026

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

Area of Science:

  • Neurology
  • Pharmacology
  • Geriatrics

Background:

  • Dementia is a progressive brain disorder causing cognitive decline.
  • Vasodilatory drugs like naftidrofuryl are used to manage dementia symptoms.
  • Systematic review is needed to assess naftidrofuryl's efficacy and safety.

Purpose of the Study:

  • To systematically evaluate the efficacy and safety of naftidrofuryl for dementia treatment.
  • To critically assess existing evidence on naftidrofuryl's clinical impact.

Main Methods:

  • Searched ALOIS specialized register for randomized placebo-controlled trials of naftidrofuryl.
  • Included nine trials with 847 patients diagnosed with various dementia types.
  • Assessed risk of bias and extracted dichotomous and continuous data.

Main Results:

  • Naftidrofuryl showed potential benefits in functional performance, behavior, mood, and cognitive function.
  • Effect sizes for performance/behavior (SMD -1.04) and mood (SMD -0.80) were statistically significant.
  • Cognitive function also showed a significant improvement (SMD -0.36).
  • However, benefits on global impression measures were inconsistent.
  • The drug was found to be well-tolerated in patients with dementia.

Conclusions:

  • Oral naftidrofuryl is generally well-tolerated by dementia patients.
  • Low-quality evidence suggests potential benefits for performance, behavior, cognition, and mood.
  • The drug's effect on global impression requires further investigation due to inconsistent findings.